3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma

Saved in:

Bibliographic Details
Published in	European journal of cancer (1990) Vol. 51; p. S663
Main Authors	Robert, C, Karaszewska, B, Schachter, J, Rutkowski, P, Mackiewicz, A, Stroyakovskiy, D, Lichinitser, M, Dummer, R, Grange, F, Mortier, L, Chiarion-Sileni, V, Drucis, K, Krajsova, I, Hauschild, A, Mookerjee, B, Legos, J, Schadendorf, D
Format	Journal Article
Language	English
Published	Elsevier Ltd 01.09.2015
Subjects	Hematology, Oncology and Palliative Medicine
Online Access	Get full text

Loading…

More Information
ISSN:	0959-8049 1879-0852
DOI:	10.1016/S0959-8049(16)31820-2